# CareCloud, Inc.: Form 10-Q for the period ended Sep 30, 2019

- Company: [CareCloud, Inc.](/companies/ccld.md) (CIK 1582982)
- Form: 10-Q
- Filed: 2019-11-06
- Accepted by EDGAR: Nov 6, 2019, 16:31 ET
- Period: 2019-09-30
- Accession: 0001493152-19-016556
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1582982/000149315219016556/form10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1582982/000149315219016556/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-30 | $16.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2019-01-01 to 2019-09-30 | $48.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months, 2019-07-01 to 2019-09-30 | $175.8k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2019-01-01 to 2019-09-30 | $648.8k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2019-07-01 to 2019-09-30 | $669.4k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-01-01 to 2019-09-30 | −$796.4k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2019-07-01 to 2019-09-30 | $87.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2019-01-01 to 2019-09-30 | $101.8k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | −$137.5k | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-01-01 to 2019-09-30 | −$1.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-07-01 to 2019-09-30 | −$0.14 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2019-01-01 to 2019-09-30 | −$0.48 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-30 | $4.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2019-01-01 to 2019-09-30 | $1.3m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | at 2019-09-30 | $14.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-30 | $26.1m | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $51.6m | us-gaap:Assets |
| Current liabilities | at 2019-09-30 | $11.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-09-30 | $14.1m | us-gaap:Liabilities |
| Shareholders' equity | at 2019-09-30 | $37.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 41,488 characters.

The following is a discussion of our consolidated financial condition and results of operations for the three and nine months ended September 30, 2019 and 2018, and other factors that are expected to affect our prospective financial condition. The following discussion and analysis should be read together with our Condensed Consolidated Financial Statements and related notes beginning on page 4 of this Quarterly Report on Form 10-Q.

Some of the statements set forth in this section are forward-looking statements relating to our future results of operations. Our actual results may vary from the results anticipated by these statements. Please see “*Forward-Looking Statements”* on page 2 of this Quarterly Report on Form 10-Q.

### Overview

MTBC, Inc., (formerly Medical Transcription Billing, Corp.) together with its consolidated subsidiaries (“MTBC” or the “Company”), is a healthcare information technology company that provides a suite of proprietary web-based solutions and business services to healthcare providers. Our integrated Software-as-a-Service (“SaaS”) platform and business services are designed to help our clients increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. These solutions and services include:

Healthcare IT:

- Revenue cycle management (“RCM”) services;
- Proprietary, healthcare IT solutions, which are part of our RCM services, including:
- Electronic health records,
- Practice management software and related tools,
- Mobile Health (“mHealth”) solutions,
- Healthcare claims clearinghouse, and
- Business intelligence, customized applications, interfaces and a variety of other technology solutions that support our healthcare clients.
- Group purchasing services.

Practice Management:

- Comprehensive practice management services.

We are able to deliver our industry-leading solutions at very competitive prices because we leverage a combination of our proprietary software, which automates our workflows and increases efficiency, together with our team of experienced health industry experts throughout the United States, who are supported by our highly educated and specialized offshore workforce of approximately 2,200 team members at labor costs that we believe are approximately one-tenth the cost of comparable U.S. employees. Our unique business model has also allowed us to become a leading consolidator in our industry sector, in which we have gained a reputation for being able to acquire and transform distressed competitors into profitable operations of MTBC.

During April 2019, the Company acquired substantially all of the revenue cycle management and practice management business of Etransmedia Technology, Inc. and its subsidiaries (together “ETM”). The Company paid $1.6 million in cash for the acquisition.

During July 2018, the Company acquired substantially all of the revenue cycle management, practice management and group purchasing assets of Orion Healthcorp, Inc. and 13 of its affiliates (together, “Orion”). The Company paid $12.6 million in cash for the acquisition. This acquisition expanded the scope of our offerings to include additional niche hospital solutions, a service that negotiates vaccine discounts with pharmaceutical manufacturers and then extends those vaccine discounts to physician members, and a service that provides end-to-end practice management services to physician practices under multi-decade management service agreements.

Adoption of our RCM solutions requires little or no upfront expenditure by a practice. Additionally, for most of our solutions and customers, our financial performance is linked directly to the financial performance of our clients because the vast majority of our revenues are based on a percentage of our clients’ collections. The standard fee for our complete, integrated, end-to-end solution is among the lowest in the industry. We currently provide services to more than 11,000 providers, (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services) practicing in approximately 1,800 independent medical practices and hospitals.

Our offshore operations in Pakistan and Sri Lanka accounted for approximately 14% and 24% of total expenses for the nine months ended September 30, 2019 and 2018, respectively. A significant portion of those foreign expenses were personnel-related costs (approximately 78% and 79% for the nine months ended September 30, 2019 and 2018). Because personnel-related costs are significantly lower in Pakistan and Sri Lanka than in the U.S. and many other offshore locations, we believe our offshore operations give us a competitive advantage over many industry participants. We are able to achieve significant cost reductions as leverage technology to reduce manual work and strategically transition a portion of the remaining manual tasks to our highly-specialized, cost-efficient team in the U.S., Pakistan and Sri Lanka.

### Key Performance Measures

We consider numerous factors in assessing our performance. Key performance measures used by management, including adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share, are non-GAAP financial measures, which we believe better enable management and investors to analyze and compare the underlying business results from period to period.

These non-GAAP financial measures should not be considered in isolation, or as a substitute for or superior to, financial measures calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Moreover, these non-GAAP financial measures have limitations in that they do not reflect all the items associated with the operations of our business as determined in accordance with GAAP. We compensate for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis, and we provide reconciliations from the most directly comparable GAAP financial measures to the non-GAAP financial measures. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

Adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share provide an alternative view of performance used by management and we believe that an investor’s understanding of our performance is enhanced by disclosing these adjusted performance measures.

Adjusted EBITDA excludes the following elements which are included in GAAP net income (loss):

- Income tax (benefit) expense or the cash requirements to pay our taxes;
- Interest expense, or the cash requirements necessary to service interest on principal payments, on our debt;
- Foreign currency gains and losses and other non-operating expenditures;
- Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
- Depreciation and amortization charges;
- Integration costs, such as severance amounts paid to employees from acquired businesses, transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
- Restructuring and impairment charges; and
- Changes in contingent consideration.

26

Set forth below is a presentation of our adjusted EBITDA for the three and nine months ended September 30, 2019 and 2018:

*($ in thousands)*

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Net revenue | $16,851 | $17,045 | $48,681 | $34,035 |
| GAAP net loss | (138) | (1,832) | (1,204) | (1,562) |
| Provision (benefit) for income taxes | 87 | (250) | 102 | (152) |
| Net interest expense | 32 | 80 | 82 | 193 |
| Foreign exchange loss (gain) / other expense | 704 | 227 | 408 | (105) |
| Stock-based compensation expense | 775 | 987 | 2,325 | 1,524 |
| Depreciation and amortization | 814 | 822 | 2,407 | 1,973 |
| Transaction and integration costs | 464 | 806 | 1,403 | 1,457 |
| Restructuring and impairment charges | 136 | - | 136 | - |
| Change in contingent consideration | (280) | 25 | (344) | 68 |
| Adjusted EBITDA | **$2,594** | **$865** | **$5,315** | **$3,396** |

Adjusted operating income and adjusted operating margin exclude the following elements which are included in GAAP operating income (loss):

- Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
- Amortization of purchased intangible assets;
- Integration costs, such as severance amounts paid to employees from acquired businesses, transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
- Restructuring and impairment charges; and
- Changes in contingent consideration.

Set forth below is a presentation of our adjusted operating income and adjusted operating margin, which represents adjusted operating income as a percentage of net revenue, for the three and nine months ended September 30, 2019 and 2018:

*($ in thousands)*

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Net revenue | $16,851 | $17,045 | $48,681 | $34,035 |
| GAAP net loss | (138) | (1,832) | (1,204) | (1,562) |
| Provision (benefit) for income taxes | 87 | (250) | 102 | (152) |
| Net interest expense | 32 | 80 | 82 | 193 |
| Other expense (income) - net | 688 | 219 | 224 | (151) |
| GAAP operating income (loss) | 669 | (1,783) | (796) | (1,672) |
| GAAP operating margin | 4.0% | (10.5%) | (1.6%) | (4.9%) |
| Stock-based compensation expense | 775 | 987 | 2,325 | 1,524 |
| Amortization of purchased intangible assets | 512 | 559 | 1,549 | 1,257 |
| Transaction and integration costs | 464 | 806 | 1,403 | 1,457 |
| Restructuring and impairment charges | 136 | - | 136 | - |
| Change in contingent consideration | (280) | 25 | (344) | 68 |
| Non-GAAP adjusted operating income | **$2,276** | **$594** | **$4,273** | **$2,634** |
| Non-GAAP adjusted operating margin | 13.5% | 3.5% | 8.8% | 7.7% |

27

Adjusted net income and adjusted net income per share exclude the following elements which are included in GAAP net income (loss):

- Foreign currency gains and losses and other non-operating expenditures;
- Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
- Amortization of purchased intangible assets;
- Integration costs, such as severance amounts paid to employees from acquired businesses, transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
- Restructuring and impairment charges;
- Changes in contingent consideration; and
- Income tax (benefit) expense resulting from the amortization of goodwill related to our acquisitions.

No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes. The following table shows our reconciliation of GAAP net loss to non-GAAP adjusted net income for the three and nine months ended September 30, 2019 and 2018:

*($ in thousands except for per share amounts)*

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| GAAP net loss | $(138) | $(1,832) | $(1,204) | $(1,562) |
| Foreign exchange loss (gain) / other expense | 704 | 227 | 408 | (105) |
| Stock-based compensation expense | 775 | 987 | 2,325 | 1,524 |
| Amortization of purchased intangible assets | 512 | 559 | 1,549 | 1,257 |
| Transaction and integration costs | 464 | 806 | 1,403 | 1,457 |
| Restructuring and impairment charges | 136 | - | 136 | - |
| Change in contingent consideration | (280) | 25 | (344) | 68 |
| Income tax expense (benefit) related to goodwill | 45 | (265) | 30 | (187) |
| Non-GAAP adjusted net income | **$2,218** | **$507** | **$4,303** | **$2,452** |

Set forth below is a reconciliation of our GAAP net loss attributable to common shareholders, per share to our non-GAAP adjusted net income per share:

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| GAAP net loss attributable to common shareholders, per share | $(0.14) | $(0.25) | $(0.48) | $(0.40) |
| Impact of preferred stock dividend | 0.13 | 0.10 | 0.38 | 0.27 |
| Net loss per end-of-period share | (0.01) | (0.15) | (0.10) | (0.13) |
| Foreign exchange loss (gain) / other expense | 0.06 | 0.02 | 0.03 | (0.01) |
| Stock-based compensation expense | 0.06 | 0.08 | 0.19 | 0.13 |
| Amortization of purchased intangible assets | 0.04 | 0.04 | 0.13 | 0.11 |
| Transaction and integration costs | 0.04 | 0.07 | 0.11 | 0.12 |
| Restructuring and impairment charges | 0.01 | - | 0.01 | - |
| Change in contingent consideration | (0.02) | 0.00 | (0.03) | 0.01 |
| Income tax expense (benefit) related to goodwill | 0.00 | (0.02) | 0.00 | (0.02) |
| Non-GAAP adjusted net income per share | **$0.18** | **$0.04** | **$0.35** | **$0.21** |
| End-of-period shares | 12,212,323 | 11,829,758 | 12,212,323 | 11,829,758 |

28

For purposes of determining non-GAAP adjusted net income per share, the Company used the number of common shares outstanding at the end of September 30, 2019 and 2018. Non-GAAP adjusted net income per share does not take into account dividends paid on our preferred stock. No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per common share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes.

### Key Metrics

In addition to the line items in our condensed consolidated financial statements, we regularly review the following metrics. We believe information on these metrics is useful for investors to understand the underlying trends in our business.

***Providers and Practices Served:*** As of September 30, 2019, we provided services to an estimated universe of more than 11,000 providers (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services), representing approximately 1,800 independent medical practices and hospitals. In addition, we served approximately 200 clients who were not medical practices, but are service organizations who serve the healthcare community. As of September 30, 2018, we served approximately more than 11,000 providers representing approximately 1,800 practices. The foregoing numbers include clients leveraging any of our products or services and are based in part upon estimates in cases where the precise number of practices or providers is unknown.

### Sources of Revenue

*Revenue:* We primarily derive our revenues from revenue cycle management services, reported in our Healthcare IT segment, which is typically billed as a percentage of payments collected by our customers. This fee includes RCM, as well as the ability to use our EHR and practice management software as part of the bundled fee. All of these services are considered revenue cycle management revenue. These services accounted for approximately 64% and 69% of our revenues during the three months ended September 30, 2019 and 2018, respectively, and 67% and 79% for nine months ended September 30, 2019 and 2018, respectively. Other Healthcare IT services, including printing and mailing operations and professional services, represented approximately 13% and 12% of revenues for the three months ended September 30, 2019 and 2018, respectively, and 12% and 11% of the revenues for the nine months ended September 30, 2019 and 2018, respectively.

As a result primarily of the Orion acquisition, we earned approximately 23% and 19% of our revenue from practice management services during the three months ended September 30, 2019 and 2018, respectively, and approximately 21% and 10% for the nine months ended September 30, 2019 and 2018, respectively. This revenue represents fees based on our actual costs plus a percentage of the operating profit and is reported in our Practice Management segment.

### Operating Expenses

*Direct Operating Costs.* Direct operating cost consists primarily of salaries and benefits related to personnel who provide services to our customers, claims processing costs, costs to operate the three managed practices, including facility lease costs, supplies, insurance and other direct costs related to our services. Costs associated with the implementation of new customers are expensed as incurred. The reported amounts of direct operating costs do not include depreciation and amortization, which are broken out separately in the condensed consolidated statements of operations.

*Selling and Marketing Expense.* Selling and marketing expense consists primarily of compensation and benefits, commissions, travel and advertising expenses.

*Research and Development Expense.* Research and development expense consists primarily of personnel-related costs and third-party contractor costs.

*General and Administrative Expense.* General and administrative expense consists primarily of personnel-related expense for administrative employees, including compensation, benefits, travel, facility lease costs and insurance, software license fees and outside professional fees.

*Contingent Consideration.* Contingent consideration represents the portion of consideration payable to the sellers of some of our acquisitions, the amount of which is based on the achievement of defined performance measures contained in the purchase agreements. Contingent consideration is adjusted to fair value at the end of each reporting period.

*Depreciation and Amortization Expense.* Depreciation expense is charged using the straight-line method over the estimated lives of the assets ranging from three to ten years. Amortization expense is charged on either an accelerated or on a straight-line basis over a period of three or four years for most intangible assets acquired in connection with acquisitions including those intangibles related to the group purchasing services. Amortization expense related to the value of our practice management clients is amortized on a straight-line basis over a period of twelve years.

*Restructuring and Impairment Charges.* Restructuring charges represent the remaining lease costs for a facility no longer used by the Company as the employees were moved to another Company facility. Impairment charges represent charges recorded for a leased facility no longer being used by the Company. The Company is marketing the facility for sublease.

*Interest and Other Income (Expense).* Interest expense consists primarily of interest costs related to our working capital line of credit, term loans and amounts due in connection with acquisitions, offset by interest income. Other income (expense) results primarily from foreign currency transaction gains (losses) and income earned from temporary cash investments.

*Income Tax.* In preparing our condensed consolidated financial statements, we estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred income tax assets and liabilities. Although the Company is forecasting a return to profitability, it incurred cumulative losses, which make realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all deferred tax assets as of September 30, 2019 and December 31, 2018.

### Critical Accounting Policies and Estimates

The critical accounting policies and estimates used in the preparation of our condensed consolidated financial statements that we believe affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements presented in this Report are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the consolidated financial statements included in our Annual Report on Form 10- K for the year ended December 31, 2018.

Except for the adoption of FASB ASC Topic 842, Leases, discussed below, there have been no material changes to our critical accounting policies and estimates during the nine months ended September 30, 2019 as compared to those reported in our Annual Report on Form 10-K for the year ended December 31, 2018.

#### Leases:

We adopted ASU 2016-02: *Leases* (Topic 842) as of January 1, 2019. We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, operating lease liability (current portion) and operating lease liability (noncurrent portion) in our condensed consolidated balance sheet at September 30, 2019. The Company does not have any finance leases.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.

We use our estimated incremental borrowing rates, which are derived from information available at the lease commencement date, in determining the present value of lease payments. We give consideration to bank financing arrangements, geographical location and collateralization of assets when calculating our incremental borrowing rates.

Our lease term includes options to extend the lease when it is reasonably certain that we will exercise that option. Leases with a term of less than 12 months are not recorded in the condensed consolidated balance sheet. Our lease agreements do not contain any residual value guarantees. For real estate leases, we account for the leased and non-leased components as a single lease component. Some leases include escalation clauses and termination options that are factored into the determination of the future lease payments when appropriate.

There have been no material changes in our critical accounting policies and estimates from those described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 20, 2019.

### Results of Operations

The following table sets forth our consolidated results of operations as a percentage of total revenue for the periods shown:

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Net revenue | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating expenses: |  |  |  |  |
| Direct operating costs | 62.5% | 71.1% | 65.3% | 61.5% |
| Selling and marketing | 2.1% | 2.7% | 2.2% | 3.4% |
| General and administrative | 26.4% | 30.1% | 28.3% | 31.7% |
| Research and development | 1.0% | 1.5% | 1.3% | 2.3% |
| Change in contingent consideration | (1.7%) | 0.1% | (0.7%) | 0.2% |
| Depreciation and amortization | 4.8% | 4.8% | 4.9% | 5.8% |
| Restructuring charges | 0.8% | 0.0% | 0.3% | 0.0% |
| Total operating expenses | 95.9% | 110.3% | 101.6% | 104.9% |
| Operating income (loss) | 4.1% | (10.3%) | (1.6%) | (4.9%) |
| Interest expense - net | 0.2% | 0.5% | 0.2% | 0.6% |
| Other (expense) income - net | (4.1%) | (1.3%) | (0.5%) | 0.4% |
| Loss before income taxes | (0.2%) | (12.1%) | (2.3%) | (5.1%) |
| Income tax provision (benefit) | 0.5% | (1.5%) | 0.2% | (0.4%) |
| Net loss | (0.7%) | (10.6%) | (2.5%) | (4.7%) |

### Comparison of the three and nine months ended September 30, 2019 and 2018

|  | Three Months Ended September 30, 2019 | 2018 | Change Amount | Percent | Nine Months Ended September 30, 2019 | 2018 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net revenue | $16,851,328 | $17,044,526 | $(193,198) | (1%) | $48,681,038 | $34,034,788 | $14,646,250 | 43% |

*Revenue.* Total revenue of $16.9 million for the three months ended September 30, 2019 decreased by $193,000 or 1% from revenue of $17.0 million for the three months ended September 30, 2018. Total revenue of $48.7 million for the nine months ended September 30, 2019 increased by $14.6 million or 43% from revenue of $34 million for the nine months ended September 30, 2018. Revenue for the three and nine months ended September 30, 2019 includes approximately $9.1 million and $26.0 million respectively, from customers acquired in the Orion and ETM acquisitions. Revenue for the three and nine months ended September 30, 2019 includes $12.6 million and $37.8 million respectively, relating to RCM clients and other revenue streams, $3.9 million and $10.1 million respectively, for practice management services and $296,000 and $701,000 respectively, related to group purchasing services.

|  | Three Months Ended September 30, 2019 | 2018 | Change Amount | Percent | Nine Months Ended September 30, 2019 | 2018 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Direct operating costs | $10,535,629 | $12,123,907 | $(1,588,278) | (13%) | $31,779,564 | $20,941,535 | $10,838,029 | 52% |
| Selling and marketing | 347,568 | 461,512 | (113,944) | (25%) | 1,091,524 | 1,169,583 | (78,059) | (7%) |
| General and administrative | 4,451,975 | 5,131,295 | (679,320) | (13%) | 13,757,805 | 10,786,234 | 2,971,571 | 28% |
| Research and development | 175,758 | 263,717 | (87,959) | (33%) | 648,822 | 768,517 | (119,695) | (16%) |
| Change in contingent consideration | (279,565) | 25,473 | (305,038) | (1,197%) | (343,768) | 68,253 | (412,021) | (604%) |
| Depreciation | 237,574 | 188,893 | 48,681 | 26% | 668,916 | 484,881 | 184,035 | 38% |
| Amortization | 576,636 | 633,205 | (56,569) | (9%) | 1,738,195 | 1,487,684 | 250,511 | 17% |
| Resturcturing and impairment charges | 136,332 | - | 136,332 | 100% | 136,332 | - | 136,332 | 100% |
| Total operating expenses | $16,181,907 | $18,828,002 | $(2,646,095) | (14%) | $49,477,390 | $35,706,687 | $13,770,703 | 39% |

*Direct Operating Costs.* Direct operating costs of $10.5 million and $31.8 million for the three and nine months ended September 30, 2019 decreased by $1.6 million or 13% and increased by $10.8 million or 52% from direct operating costs of $12.1 million and $20.9 million for the three and nine months ended September 30, 2018, respectively. During the three months ended September 30, 2019, salary costs decreased by $697,000 and outsourcing and processing costs decreased by $1.1 million. During the nine months ended September 30, 2019, salary costs increased by $5.8 million and outsourcing and processing costs increased by $838,000. Facility costs decreased by $8,000 for the three months ended September 30, 2019 and increased by $960,000 for the nine months ended September 30, 2019. Medical supplies for the managed practices increased by $196,000 and $2.6 million for the three and nine months ended September 30, 2019, respectively. Postage and delivery costs increased by $39,000 and $284,000, respectively for the three and nine months ended September 30, 2019. The increase in the costs for the three and nine months ended September 30, 2019 were primarily related to the Orion and Etransmedia acquisitions.

*Selling and Marketing Expense.* Selling and marketing expense of $348,000 and $1.1 million for the three and nine months ended September 30, 2019 decreased by $114,000 or 25% and by $78,000 or 7% from selling and marketing expense of $462,000 and $1.2 million for the three and nine months ended September 30, 2018, respectively.

*General and Administrative Expense.* General and administrative expense of $4.5 million and $13.8 million for the three and nine months ended September 30, 2019 decreased by $679,000 or 13% and increased by $3.0 million or 28% compared to the same period in 2018. The increase in general and administrative expense for the nine months ended September 30, 2019 was primarily related to additional salaries, facility costs and professional fees as a result of the Orion and Etransmedia acquisitions. The decrease in general and administrative expense for the three months ended September 30, 2019 was primarily due to a reduction in headcount subsequent to the acquisitions.

*Research and Development Expense.* Research and development expense of $176,000 and $649,000 for the three and nine months ended September 30, 2019 decreased by $88,000 and $120,000 from research and development expense of $264,000 and $769,000 for the three and nine months ended September 30, 2018, respectively. During the three and nine months ended September 30, 2019, the Company capitalized approximately $194,000 and $372,000 respectively of development costs in connection with its internal-use software.

*Contingent Consideration.* The change in contingent consideration of $412,000 for the nine months ended September 30, 2019 when compared to nine months ended September 30, 2018, was due to favorable settlements of the amount due to the owners of companies previously acquired.

*Depreciation.* Depreciation of $238,000 and $669,000 for the three and nine months ended September 30, 2019 increased by $49,000 or 26% and $184,000 or 38% from depreciation of $189,000 and $485,000 for the three and nine months ended September 30, 2018, respectively, primarily due to additional purchases and the property and equipment acquired as part of the Orion and ETM acquisitions.

*Amortization Expense.* Amortization expense of $577,000 and $1.7 million for the three and nine months ended September 30, 2019, respectively, decreased by $57,000 or 9% and increased by $251,000 or 17% from amortization expense of $633,000 and $1.5 million for the three and nine months ended September 30, 2018, respectively. The increase for the nine months ended September 30, 2019 was primarily related to the intangible assets acquired from the Orion and Etransmedia acquisitions. The decrease in amortization expense for the three months ended September 30, 2019 was due to intangibles related to the Company’s previous acquisitions becoming fully amortized.

*Restructuring and Impairment Charges.* Restructuring charges represent the remaining lease costs for a facility no longer used by the Company as the employees were moved to another Company facility. Impairment charges represent charges recorded for a leased facility no longer being used by the Company. The Company is marketing the facility for sublease.

|  | Three Months Ended September 30, 2019 | 2018 | Change Amount | Percent | Nine Months Ended September 30, 2019 | 2018 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest income | $57,272 | $24,544 | $32,728 | 133% | $202,969 | $59,768 | $143,201 | 240% |
| Interest expense | (88,925) | (104,872) | 15,947 | (15%) | (284,883) | (253,120) | (31,763) | 13% |
| Other (expense) income - net | (688,342) | (218,721) | (469,621) | 215% | (224,151) | 151,242 | (375,393) | (248%) |
| Income tax provision | 86,970 | (250,072) | 337,042 | (135%) | 101,790 | (151,872) | 253,662 | (167%) |

*Interest Income.* Interest income of $57,000 and $203,000 for the three and nine months ended September 30, 2019 increased by $33,000 or 133% and $143,000 or 240% from interest income of $25,000 and $60,000 for the three and nine months ended September 30, 2018, respectively. The interest income represents interest earned on temporary cash investments.

*Interest Expense.* Interest expense of $89,000 and $285,000 for the three and nine months ended September 30, 2019, respectively, decreased by $16,000 or 15% and increased by $32,000 or 13% from interest expense of $105,000 and $253,000 for the three and nine months ended September 30, 2018, respectively. The increase for the nine months ended September 30, 2019 was primarily due to the additional vehicle financing obtained. Interest expense includes the amortization of deferred financing costs, which was $144,000 and $143,000 during the nine months ended September 30, 2019 and 2018, respectively.

*Other (Expense) Income - net.* Other expense - net was $688,000 and $224,000 for the three and nine months ended September 30, 2019, respectively compared to other expense - net of $219,000 and other income - net of $151,000 for the three and nine months ended September 30, 2018, respectively. Other (expense) income primarily represents foreign currency transaction gains (losses) resulting from transactions in foreign currencies other than the functional currency. These transaction gains and losses are recorded in the condensed consolidated statements of operations related to the recurring measurement and settlement of such transactions.

*Income Tax Provision.* There were $87,000 and $102,000 provisions for income taxes for the three and nine months ended September 30, 2019, respectively, compared to income tax benefits of $250,000 and $152,000 for the three and nine months ended September 30, 2018, respectively. As a result of the Company incurring a tax loss for 2018, which has an indefinite life under the current tax rules, the federal deferred tax liability was offset against the federal net operating loss to the extent allowable in 2018. The current income tax provision for the three and nine months ended September 30, 2019 was approximately $37,000 and $67,000, and primarily relates to state minimum taxes and foreign income taxes. Although the Company is forecasting a return to profitability, it has incurred losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance was recorded against all deferred tax assets at September 30, 2019 and 2018.

### Liquidity and Capital Resources

Borrowings under the SVB facility are based on 200% of repeatable revenue, reduced by an annualized attrition rate as defined in the agreement. As of September 30, 2019, nothing was drawn on the SVB credit agreement.

During the nine months ended September 30, 2019, there was positive cash flow from operations of approximately $4.8 million and as of September 30, 2019 the Company had approximately $14.0 million in cash, positive working capital of $14.8 million and no bank debt.

During the second quarter of 2019, the Company paid the purchase price of $1.6 million for the ETM acquisition in cash.

During 2018, the Company paid the purchase price of $12.6 million for the Orion acquisition in cash. The Company occasionally utilizes its revolving line of credit with SVB, but, as of September 30, 2019, there was no balance outstanding. SVB doubled the maximum availability on the line from $5 million to $10 million in September 2018. During April 2018, the Company sold 420,000 shares of Series A Preferred Stock and raised net proceeds of approximately $9.4 million. During October 2018, the Company sold 600,000 additional shares of its Series A Preferred Stock raising net proceeds of approximately $13.4 million.

In connection with the Company’s July 2019 Form S-3, the Company entered into an At the Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley FBR, Inc. (“B. Riley FBR”), relating to the sale of up to $10.0 million of the Company’s Series A Preferred Stock. Under the Sales Agreement, the Company pays B. Riley FBR a commission rate of 3.0% of the gross proceeds from the sale of any shares of Series A Preferred Stock.

Beginning with the quarter ended September 30, 2019, 145,184 shares of the Company’s Series A Preferred Stock were sold pursuant to the Sales Agreement and the net proceeds to the Company from the sale of the Series A Preferred Stock were approximately $3.7 million after deducting commissions paid of approximately $118,000.

The following table summarizes our cash flows for the periods presented:

|  | Three Months Ended September 30, 2019 | 2018 | Nine Months Ended September 30, 2019 | 2018 |
| --- | ---: | ---: | ---: | ---: |
| Net cash provided by operating activities | $1,440,872 | $2,780,897 | $4,753,801 | $4,748,502 |
| Net cash used in investing activities | (422,430) | (11,966,685) | (2,926,650) | (13,343,115) |
| Net cash provided by (used in) financing activities | 1,719,201 | (1,427,406) | (2,538,807) | 5,776,640 |
| Effect of exchange rate changes on cash | 666,528 | 150,149 | 226,370 | (284,685) |
| Net increase (decrease) in cash | $3,404,171 | $(10,463,045) | $(485,286) | $(3,102,658) |

The loss before income taxes was $51,000 and $1.1 million for the three and nine months ended September 30, 2019, respectively, which included $814,000 and $2.4 million of non-cash depreciation and amortization, respectively. The loss before tax for the three and nine months ended September 30, 2018 was $2.1 million and $1.7 million, respectively, which included $822,000 and $2.0 million of non-cash depreciation and amortization, respectively.

### Operating Activities

Cash provided by operating activities was $4.8 million during both the nine months ended September 30, 2019 and September 30, 2018. The decrease in the net loss of $358,000 for the nine months ended September 30, 2019 as compared to the same period in 2018 included the following changes in non-cash items: an increase in depreciation and amortization of $442,000, an decrease in stock based compensation expense of $801,000, a change in the provision (benefit) for deferred income taxes of $222,000 and an increase in interest accretion of $239,000.

The net change in operating assets and liabilities was $3.5 million. Accounts receivable decreased by $127,000 for the nine months ended September 30, 2019, compared with a decrease of $902,000 for the nine months ended September 30, 2018. Accounts payable, accrued compensation and accrued expenses increased by $698,000 for the nine months ended September 30, 2019 compared to a decrease of $2.4 million for the nine months ended September 30, 2018. For the three and nine months ended September 30, 2019, the change in the lease liabilities is included in this amount.

### Investing Activities

Capital expenditures were $1.3 million and $743,000 for the nine months ended September 30, 2019 and 2018, respectively. The capital expenditures for the nine months ended September 30, 2019 primarily represented computer equipment purchased for the Pakistan office and $372,000 of capitalized development costs in connection with internal-use software.

### Financing Activities

Cash used in financing activities during the nine months ended September 30, 2019 was $2.5 million and cash provided by financing activities was $5.8 million for the nine months ended September 30, 2018. Cash used in financing activities during the nine months ended September 30, 2019 included $290,000 of repayments for debt obligations, $4.5 million of preferred stock dividends and $1.3 million of tax withholding obligations paid in connection with stock awards issued to employees. Cash provided by financing activities included $9.4 million of net proceeds from issuing 420,000 shares of Preferred Stock during the nine months ended September 30, 2018 and $3.7 million from issuing Preferred Stock during the nine months ended September 30, 2019. Cash used in financing activities for nine months ended September 30, 2018 included $329,000 of repayment for debt obligations, $2.8 million of preferred stock dividends and $333,000 of tax withholding obligations paid in connection with stock awards issued to employees. There were no bank borrowings or bank debt repayments during the nine months ended September 30, 2019.

### Contractual Obligations and Commitments

We have contractual obligations under our line of credit. We also maintain operating leases for property and certain office equipment. We were in compliance with all SVB covenants as of September 30, 2019. For additional information, see Contractual Obligations and Commitments under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 20, 2019.

### Off-Balance Sheet Arrangements

As of September 30, 2019, and 2018, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special-purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

## Market risk

As filed, 175 characters.

We are a smaller reporting company as defined by 17 C.F.R. 229.10(f)(1) and are not required to provide information under this item, pursuant to Item 305(e) of Regulation S-K.

## Controls and procedures

As filed, 2,558 characters.

#### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, based on the 2013 framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2019 as required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures, as of September 30, 2019, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

#### Changes in Internal Control Over Financial Reporting

Beginning January 1, 2019, we implemented ASC 842, “*Leases.”* For its adoption, we implemented changes to our lease identification processes and control activities within them such as development of new entity-wide policies, in-house training, ongoing contract reviews and system changes to accommodate presentation and disclosure requirements.

There were no other changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 147 characters.

Pursuant to the instructions of Item 1A of Form 10-Q, a smaller reporting company is not required to provide the information required by this Item.

Filed Nov 6, 2019.
Source: SEC EDGAR, the filing index for accession 0001493152-19-016556. Last ingested by Listed: Nov 5, 2026, 18:58 ET. No prices; not investment advice.
